Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID-19 in New Zealand

Arthritis Rheumatol. 2021 May;73(5):896-897. doi: 10.1002/art.41643. Epub 2021 Mar 7.

Authors

Eamon Duffy¹, Nicola Arroll¹, Richard Beasley², Thomas Hills³

Affiliations

¹ Auckland District Health Board, Auckland, New Zealand.
² Medical Research Institute of New Zealand and Capital and Coast District Health Board, Wellington, New Zealand.
³ Auckland District Health Board Auckland, New Zealand and Medical Research Institute of New Zealand, Wellington, New Zealand.

PMID: 33410583
DOI: 10.1002/art.41643

No abstract available

Publication types

Letter

MeSH terms

Antirheumatic Agents / supply & distribution*
Antirheumatic Agents / therapeutic use*
COVID-19 Drug Treatment*
Drug and Narcotic Control*
Evidence-Based Medicine
Health Services Accessibility*
Humans
Hydroxychloroquine / supply & distribution*
Hydroxychloroquine / therapeutic use*
New Zealand
Off-Label Use
Practice Patterns, Physicians'
Rheumatic Diseases / drug therapy*
SARS-CoV-2
United States

Substances

Antirheumatic Agents
Hydroxychloroquine